WGS — GeneDx Holdings Corp. stock price, charts and financials

QT70GeneDx Holdings Corp.

GeneDx Holdings Corp. (NASDAQ: WGS) is a Healthcare company in the Medical - Healthcare Information Services industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
79.08
+2.00+2.59%
OverviewShort InterestFilings
WGSQT70GeneDx Holdings Corp.·NASDAQ
79.08+2.59%
TA
Loading chart...
Signal & projected range
Earnings big beat — drift (PEAD)Historical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Premium shows the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands ofhistorical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
PGNY+0.55%$28.25HTFL+2.95%$29.67PRVA-1.46%$22.12OMDA+3.58%$24.52TDOC-0.14%$7.12CERT-1.97%$8.04GDRX+3.26%$3.80WAY+2.50%$24.84
Snapshot
Index-P/E-EPS (ttm)-2.66Insider Own-Shs Outstand29.82MPerf Week18.38%
Market Cap2.30BForward P/E68.67EPS next Y1.12Insider Trans20.58%Shs Float27.53MPerf Month11.08%
Enterprise Value2.41BPEG-EPS next Q-Inst Own-Short Float21.18%Perf Quarter90.32%
Income-106.66MP/S5.06EPS this Y98.76%Inst Trans-Short Ratio4.44Perf Half Y-8.33%
Sales454.42MP/B9.38EPS next Y3516.32%ROA-22.09%Short Interest5.83MPerf YTD-40.74%
Book/sh-P/C-EPS next 5Y-ROE-38.72%52W High175.30 -54.89%Perf Year-27.18%
Cash/sh-P/FCF-EPS past 3/5Y-ROIC-14.69%52W Low33.05 139.30%Perf 3Y920.93%
Dividend Est.-EV/EBITDA-Sales past 3/5Y22.12% 19.05%Gross Margin68.20%Volatility11.66% 8.21%Perf 5Y-79.29%
Dividend TTM-EV/Sales5.29EPS Y/Y TTM-37.11%Oper. Margin-13.34%ATR (14)5.60Perf 10Y-
Dividend Ex-Date-Quick Ratio3.06Sales Y/Y TTM45.25%Profit Margin-23.40%RSI (14)66.32Recom2.09
Dividend Gr. 3/5Y-Current Ratio3.30EPS Q/Q-200.00%SMA2018.54%Beta1.99Target Price89.57
Payout0.00%Debt/Eq0.69Sales Q/Q17.24%SMA5023.63%Rel Volume0.99Prev Close77.08
Employees1,300LT Debt/Eq0.46EarningsOct 27SMA200-14.15%Avg Volume1.08MPrice79.08
IPO DateNov 04, 2020Option/ShortYes / YesEPS/Sales Surpr.-1766.67% -9.07%Net Debt/EBITDA-1.40Volume1,068,687Change2.59%
Analyst Ratings
DateActionAnalystRatingTarget
Aug-04-26ReiteratedCanaccord GenuityBuy$75 → $90
Jun-29-26ReiteratedGuggenheimBuy$70 → $74
Jun-23-26ReiteratedPiper SandlerOverweight$130 → $63
May-05-26ReiteratedCraig-HallumBuy$153 → $85
May-05-26ReiteratedCanaccord GenuityBuy$100 → $75
May-05-26ReiteratedBTIGBuy$170 → $90
May-05-26ReiteratedGuggenheimBuy$170 → $70
May-05-26ReiteratedWells FargoOverweight$155 → $75
Apr-20-26ReiteratedCanaccord GenuityBuy$170 → $100
Feb-24-26ReiteratedPiper SandlerOverweight$120 → $130
Latest News
Aug-06-26
Aug-06-2604:05PM
GeneDx to Participate in Upcoming Investor Conferencesbusinesswire.com
Aug-04-26
Aug-04-2608:21AM
Canaccord Genuity Maintains Buy on GeneDx Holdings, Raises Price Target to $90Benzinga
Aug-03-26
Aug-03-2608:59PM
GeneDx Holdings Corp. (WGS) Q2 2026 Earnings Call Transcriptseekingalpha.com
07:04PM
GeneDx Q2 Earnings Call Highlightsmarketbeat.com
06:46PM
GeneDx Holdings Corp. (WGS) Q2 Earnings and Revenues Surpass Estimateszacks.com
04:05PM
GeneDx Reports Second Quarter 2026 Financial Resultsbusinesswire.com
12:00PM
CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds GeneDx (WGS) Investors of Securities Class Action Lawsuit Deadline on August 3, 2026gurufocus.com
09:53AM
WGS Investors Have Opportunity to Lead GeneDx Holdings Corp. Securities Fraud Lawsuit with SBS Lawglobenewswire.com
02:54AM
DEADLINE TODAY: GeneDx Holdings Corp. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - WGSprnewswire.com
01:41AM
DEADLINE TODAY: GeneDx Holdings Corp. Investor Alert: Contact SBS by August 3, 2026 for Opportunity to Lead Securities Fraud Lawsuitprnewswire.com
Aug-02-26
Aug-02-2612:46PM
WGS SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Reminds GeneDx (WGS) Investors of Securities Class Action Lawsuit Deadline on August 3, 2026newsfilecorp.com
12:00PM
Bronstein, Gewirtz & Grossman LLC Urges GeneDx Holdings Corp. Investors to Act: Class Action Filed Alleging Investor Harmglobenewswire.com
09:15AM
WGS DEADLINE TOMORROW: ROSEN, A LONGSTANDING LAW FIRM, Encourages GeneDx Holdings Corp. Investors to Secure Counsel Before Important August 3 Deadline in Securities Class Action - WGSnewsfilecorp.com
Aug-01-26
Aug-01-2605:55PM
WGS Deadline: WGS Investors with Losses in Excess of $100K Have Opportunity to Lead GeneDx Holdings Corp. Securities Fraud Lawsuitprnewswire.com
11:27AM
WGS DEADLINE MONDAY: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages GeneDx Holdings Corp. Investors with Losses in Excess of $100K to Secure Counsel Before Important August 3 Deadline in Securities Class Action - WGSglobenewswire.com
Company

GeneDx Holdings Corp. functions as a health intelligence firm singularly focused on the individual patient. It aims to revolutionize healthcare delivery by deploying advanced artificial intelligence and machine learning capabilities. These sophisticated algorithms are applied to vast, longitudinal clinical and genomic datasets to construct comprehensive, dynamic models of human health, ultimately defining personalized, optimal pathways for each person's well-being. Through its exclusive Centrellis health intelligence platform, the company gains profound insights into both disease states and overall wellness, enabling it to furnish evidence-based solutions for the most critical medical challenges. Eric Schadt established the corporation in October 2015, and its principal offices are located in Stamford, Connecticut.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
Total Revenue454428305—————
Cost of Goods Sold Incl. D&A144129111—————
Gross Profit310298194—————
Selling, General and Administrative Excl. Other292239168—————
Research and Development847246—————
Other Operating Expense-504—————
Operating Income-60-12-23—————
Interest Expense433—————
Unusual Expense
————————
Non-Operating Income (Expense)-44-7-26—————
Net Income Before Taxes-105-21-53—————
Income Taxes
100—————
Consolidated Net Income-107-21-52—————
Net Income From Continuing Operations-108-21-52—————
Net Income-107-21-52—————
EPS (Recurring)-3.64-0.73-1.94—————
EPS (Basic, Before Extraordinaries)-3.64-0.73-1.94—————
EPS (Diluted)-3.62-0.73-1.94—————
EBITDA-767-28—————
Other After Tax Adjustments
————————
Stock Option Compensation Expense
————————
Price To Earnings Ratio
————————
Price To Sales Ratio5.238.206.80—————
Gross Margin68.2869.6363.61—————
Operating Margin-13.22-2.80-7.54—————
Net Margin-23.57-4.91-17.05—————
Shares Outstanding302727—————
Market Capitalization2,3723,5122,075—————
Operating Lease Expense
————————
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
$187.47$144.24$101.02$57.79$14.56● Close Price0.00M20.51M41.02M61.52M82.03MUSD Trades VolumeAugSepOctNovDec2026FebMarAprMayJunJulAug
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Ryan JasonDirectorJun 18 '26Option Exercise0.003,576015,480Jun 23
RUCH JOSHUADirectorJun 18 '26Option Exercise0.003,576033,299Jun 23
PFENNIGER RICHARD C JRDirectorJun 18 '26Option Exercise0.003,576045,082Jun 23
Meister Keith A.director, 10 percent owner:Jun 18 '26Option Exercise0.003,576023,705Jun 23
Leproust Emily M.DirectorJun 18 '26Option Exercise0.003,576024,852Jun 23
Casdin Elidirector, 10 percent owner:Jun 18 '26Option Exercise0.003,576024,093Jun 23
Feeley KevinCHIEF FINANCIAL OFFICERJun 16 '26Option Exercise0.007,197043,683Jun 18
Feeley KevinCHIEF FINANCIAL OFFICERJun 16 '26Sale60.773,729226,59739,954Jun 18
Stueland KatherineCHIEF EXECUTIVE OFFICERJun 16 '26Option Exercise0.0018,7500114,873Jun 18
Stueland KatherineCHIEF EXECUTIVE OFFICERJun 16 '26Sale60.7710,501638,104104,372Jun 18
Feeley KevinCHIEF FINANCIAL OFFICERJun 09 '26Option Exercise0.002,462037,752Jun 11
Feeley KevinCHIEF FINANCIAL OFFICERJun 09 '26Sale53.771,26668,07336,486Jun 11
Stueland KatherineCHIEF EXECUTIVE OFFICERJun 09 '26Option Exercise0.006,546099,762Jun 11
Stueland KatherineCHIEF EXECUTIVE OFFICERJun 09 '26Sale53.773,639195,66996,123Jun 11
Casdin Capital, LLCdirector, 10 percent owner:Jun 05 '26Buy52.8650,0002,642,8303,707,164Jun 08
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.